Virtual Care in Oncology

Virtual Care in Oncology: What the Evidence Shows

Ask an Australian oncology provider what virtual care delivers and you will hear about reduced hospitalisations, improved quality of life, and better treatment completion. Those are reasonable things to want. They are not, consistently, what the completed trials show.

That gap matters before insurers fund it at scale.

What the trials found

The TeleCaRe RCT, published in the Journal of Physiotherapy (2026), ran an eight-week virtual group exercise program across Melbourne health networks. Two hundred and seventeen participants. Videoconferencing, twice weekly, against a single face-to-face physiotherapy session. On the primary endpoint, quality of life at nine weeks, the virtual program fell below the minimum clinically important threshold. It cost roughly four times as much per person. Unplanned hospitalisations were statistically identical across groups.

The ESCAPI trial (Supportive Care in Cancer, 2024, n=346) tested a community-nurse shared-care pathway for chemotherapy outpatients in Sydney. Hospital presentations fell 12% in the intervention arm. Meaningful direction. Not statistically significant. Treatment completion was 85.3% versus 85.8%. Effectively the same.

These are not failures. They are findings. The difference matters.

What the evidence supports

Ninety per cent of patients at St George and Sutherland Hospitals wanted another telehealth consultation after their first (JCO Global Oncology, 2024). Ninety-three per cent acceptability in a matched Victorian cancer centre study. These are not soft metrics in a population managing treatment, side effects, and the psychological weight of a serious illness.

ESCAPI found one significant clinical effect. Self-efficacy, a patient’s confidence in managing their own health, improved meaningfully in the coordinated care group: +4.3 points on the Cancer Behavior Inventory, p=0.02. In cancer care, that confidence predicts adherence and long-term health behaviour.

The equity case is also real. The Clinical Oncology Society of Australia’s teleoncology guidelines, the first oncology-specific telehealth guidelines produced anywhere in the world, underpin current Australian practice. The North Queensland Teleoncology Network has demonstrated safe remote-supervised chemotherapy and used travel cost savings to fund a trainee oncologist in Mount Isa.

The question insurers should be asking

The case for virtual oncology support rests on access, patient experience, and self-efficacy. Distance is a genuine barrier to cancer treatment in Australia. That case is strong without overstating it.

Programs that measure self-efficacy, satisfaction, care coordination, and escalation time can demonstrate value. Programs that claim hospitalisation reductions without the trial evidence will not hold up to a procurement team that reads the primary literature.

The evidence is there. It just needs to be cited accurately.

Learn more about how Spectrum.Life’s Cancer Care Program is designed around what the evidence supports.